Clinical trials: Lou Gehrig's Disease
Amyotrophic Lateral Sclerosis
The National Amyotrophic Lateral Sclerosis Registry
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be…
- Trial name
- NCT01772602
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Centers for Disease Control and Prevention
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05740813
- Testing
- ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis, Sialorrhea
Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in…
- Trial name
- NCT00125203
- Testing
- Botulinum toxin type B (Myobloc), Injection of salivary glands
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05136885
- Testing
- SLS-005
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis
Intermediate-Sized Expanded Access Study
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
- Trial name
- NCT05597436
- Testing
- Trehalose
- Where
- 21 sites in United States
- Sponsor
- Seelos Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease.
- Trial name
- Lithium (NCT00790582)
- Testing
- lithium carbonate
- Where
- 10 sites in United States
- Volunteers
- 109 people
- Sponsor
- Forbes Norris MDA/ALS Research Center
Amyotrophic Lateral Sclerosis
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by…
- Trial name
- JETALS (NCT03548311)
- Testing
- methylcobalamin, saline solution
- Where
- 16 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Eisai Co., Ltd.
Amyotrophic Lateral Sclerosis
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory…
- Trial name
- NCT04428775
- Testing
- ALZT-OP1a (cromolyn)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- AZTherapies, Inc.
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Rehabilitation in SOD1 ALS Treated With Tofersen
The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT05725759
- Testing
- Rehabilitation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Amyotrophic Lateral Sclerosis
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of arimoclomol in subjects with SOD1 positive familial Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT00706147
- Testing
- Arimoclomol
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative…
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases
- Trial name
- BIO_ALS-01 (NCT00677768)
- Testing
- No intervention
- Where
- 30 sites in United States, Canada
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS).
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- Trial name
- BANYAN (NCT07688239)
- Testing
- Foralumab Nasal
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tiziana Life Sciences LTD
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen G DNL343
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05842941
- Testing
- DNL343
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase…
- Trial name
- NCT00561366
- Testing
- Arimoclomol
- Where
- 35 sites in United States, Canada
- Sponsor
- CytRx
Amyotrophic Lateral Sclerosis
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04326283
- Testing
- Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- Genuv Inc.
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis
Genetics of Familial and Sporadic ALS
We are collecting blood samples, clinical and family information from ALS (amyotrophic lateral sclerosis) patients and their families to identify causes of ALS and ALS/dementia.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease
- Trial name
- ALS (NCT00821132)
- Testing
- Genetic study of ALS families
- Where
- United States
- Volunteers
- 13,521 people, healthy volunteers welcome
- Sponsor
- Northwestern University
ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis (ALS)
A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to investigate the efficacy and confirm the safety of E0302 in patients with Amyotrophic Lateral Sclerosis (ALS) by assessing changes in scores of survival rate and functional rating scale.
- Trial name
- NCT00444613
- Testing
- E0302 (mecobalamin)
- Where
- 44 sites in Japan
- Volunteers
- 373 people
- Sponsor
- Eisai Co., Ltd.
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals